15 related articles for article (PubMed ID: 38713408)
1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A; Guven DC; Koksal B; Karaoglan BB; Kivrak D; Ismayilov R; Aslan F; Sutcuoglu O; Yazici O; Kadioglu A; Alan O; Majidova N; Erciyestepe M; Ozcan E; Akdag G; Taban H; Kaya AO; Guliyev M; Yildirim N; Sakalar T; Yazilitas D; Unal C; On S; Biter S; Demirci NS; Senler FC; Kemal Y; Halil OD; Gullu I; Aksoy S
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38795147
[TBL] [Abstract][Full Text] [Related]
2. Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.
Samlowski W; Silver MA; Hohlbauch A; Zhang S; Fukunaga-Kalabis M; Krepler C; Wang Y; Sruti I; Jiang R
Melanoma Res; 2024 May; ():. PubMed ID: 38814728
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Larkin J; Weber J; Del Vecchio M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; De la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Mandalá M
Eur J Cancer; 2022 Sep; 173():285-296. PubMed ID: 35964471
[TBL] [Abstract][Full Text] [Related]
4. Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis.
Digkas E; Tabiim AJ; Smith D; Valachis A
Target Oncol; 2022 Sep; 17(5):507-515. PubMed ID: 35913645
[TBL] [Abstract][Full Text] [Related]
5. Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States.
Zhang Q; Gossai A; Monroe S; Nussbaum NC; Parrinello CM
Health Serv Res; 2021 Dec; 56(6):1281-1287. PubMed ID: 33998685
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Therapy of Melanoma.
Tarhini AA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
8. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
[TBL] [Abstract][Full Text] [Related]
9. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician.
Blonde L; Khunti K; Harris SB; Meizinger C; Skolnik NS
Adv Ther; 2018 Nov; 35(11):1763-1774. PubMed ID: 30357570
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
[TBL] [Abstract][Full Text] [Related]
11. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.
Xu S; Ross C; Raebel MA; Shetterly S; Blanchette C; Smith D
Value Health; 2010; 13(2):273-7. PubMed ID: 19912596
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
